Provides specialized diagnostic imaging services, primarily to cardiologists, internal medicine physicians, and family practice doctors. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 13% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades below its recent peak — about 15% off the top. A pullback, not a collapse.
Over the last 4 years, sales grew about 13% a year on average.
Sales run at $172.2M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 86 buys and 39 sells. Management buying with its own money is usually read as a good sign.
A loss of $5.9M against $172.2M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 21/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 36/100.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.